Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D9-methyl-alpha-glycerophosphocholine (D9-GPC) is a stable isotope-labeled (deuterium-labeled) form of alpha-glycerophosphocholine, a naturally occurring choline-containing phospholipid found in breast milk. It is used as an investigational tracer in pharmacokinetic and metabolic studies to track the distribution and utilization of choline. Specifically, it has been studied by the Universitätsklinikum Tübingen in Germany to evaluate choline metabolism in preterm infants (28–32 weeks gestation). The compound serves as a labeled choline supplement, allowing researchers to assess the kinetics of D9-choline, D9-betaine, and D9-phosphatidylcholine (D9-PC) in plasma. This research aims to optimize choline supplementation strategies to support neurodevelopment and organ maturation in infants with nutritional deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d9-methyl-alpha-glycerophosphocholine.